Position in URGN
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$220,800
New position
Shares Held
6,000
first reported quarter
Ownership
0.012%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#3
of 4 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Brookstone Capital Management holds $3,313,596 across 9 Biotechnology names. URGN ranks #5 (6.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TGTX |
Tg Therapeutics, Inc.
|
17,521 | $962,603 | |
| 2 | EXEL |
Exelixis, Inc.
|
16,029 | $872,137 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
11,032 | $863,474 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
500 | $248,365 | |
| 5 | URGN |
UroGen Pharma Ltd.
This page
|
6,000 | $220,800 | |
| 6 | IOVA |
Iovance Biotherapeutics, Inc.
|
22,607 | $94,045 | |
| 7 | BDTX |
Black Diamond Therapeutics, Inc.
|
13,484 | $24,945 | |
| 8 | GUTS |
Fractyl Health, Inc.
|
21,272 | $16,889 |
All Filings in URGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $220,800 | 6,000 | Shares | Sole | 2026-07-15 | |
| No filing history on record for this holder in this stock. | ||||||